ABSTRACT
Semiconducting nanoparticles with luminescent properties are used as detection probes and drug carriers in in-vitro and in-vivo analysis. ZnO nanoparticles, due to its biocompatibility and low cost, have shown potential application in bioimaging and drug delivery. Thus, ZnO/SiO2 core/shell nanoparticle was synthesised by wet chemical method for fluorescent probing and drug delivery application. The synthesised core/shell nanomaterial was characterized using XRD, FTIR, UV-VIS spectroscopy, Raman spectroscopy, TEM and PL analysis. The silicon shell enhances the photoluminescence and aqueous stability of the pure ZnO nanoparticles. The porous surface of the shell acts as a carrier for sustained release of curcumin. The synthesized core/shell particle shows high cell viability, hemocompatibility and promising florescent property. Graphical Abstract.
Subject(s)
Antineoplastic Agents/pharmacology , Curcumin/pharmacology , Drug Delivery Systems , Nanoparticles/chemistry , Silicon Dioxide/chemistry , Zinc Oxide/chemistry , Animals , Antineoplastic Agents/chemistry , Cell Survival/drug effects , Curcumin/chemistry , Dose-Response Relationship, Drug , Drug Carriers/chemical synthesis , Drug Carriers/chemistry , Healthy Volunteers , Humans , Mice , NIH 3T3 Cells , Optical Imaging , Silicon Dioxide/chemical synthesis , Zinc Oxide/chemical synthesisABSTRACT
Hydroxyapatite (HAP) is the main constituent of human bone and teeth. Hydroxyapatite nanoparticles are used for the treatment of various bone infections. Nanohydroxyapatite is a biocompatible material. It is used as a drug carrier for drugs and biomolecules for various diseases. Hydroxyapatite nanoparticles are made into nanocomposite with sodium alginate and polyvinyl alcohol. This nanocomposite is used for the sustained release of drugs. It is characterized by various characterization techniques like XRD, FTIR, TEM, and Raman. Hydroxyapatite nanoparticles are coated initially with polyvinyl alcohol and then coated with sodium alginate. Amoxicillin is used as the model drug. Studies on the drug loading and drug release have been done. The release of the drug is sustained for about 30 days. Antimicrobial studies have shown good activity against pathogens. The zone of inhibition is found to be 18 mm for a concentration of 500 µg against Bacillus subtilis and 16 µg against Klebsiella pneumonia.
